<DOC>
	<DOC>NCT00706589</DOC>
	<brief_summary>The purpose of this trial is to demonstrate the efficacy and safety of aripiprazole in children and adolescents aged 6~18 years with chronic tic disorders or Tourette's disorder</brief_summary>
	<brief_title>Aripiprazole in Children and Adolescents With Chronic Tic Disorder or Tourette's Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Tic Disorders</mesh_term>
	<mesh_term>Tics</mesh_term>
	<mesh_term>Tourette Syndrome</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>1. Patients who can provide an assent form signed by themselves and informed consent form by their legal representatives prior to performing of any study procedures. 2. Male or female children and adolescents aged 6 to 18 years 3. Patients who are diagnosed with chronic tic disorders(Motor or Phonic) or Tourette's disorder according to DSMIV(Diagnostic and Statistical Manual of Mental DisordersFourth Edition)(using KSADSPLK (KiddleSchedule for Affective Disorders and Schizophrenia,Present and Lifetime VersionKorean version)) and require drug therapy. 4. The total tic score of the KYGTSS (Korean version of Yale Global Tic Severity Scale)is more than 22 at baseline 1. Patients with secondary tic symptoms accompanied by Tardive tics, Huntington disease, neuroacanthocytosis, mental retardation, or autism 2. Patients with IQ (Intelligence quotient) (assessed using KEDIWISC (Korean educational Development InstituteWechsler Intelligence Scale for children)) 70 and lower than 70 3. Patients with a history of neuroleptic malignant syndrome 4. Patients with antipsychotic or alcohol use disorder (abuse, dependence, and/or withdrawal) according to DSMIV criteria for the past 3 months 5. Patients with a history of allergy or hypersensitivity reaction to aripiprazole 6. Patients with a history of resistance to treatment with antipsychotics 7. Patients who have participated in another clinical study within 1 month prior to screening 8. Patients who have previously taken aripiprazole or participated in a clinical study with aripiprazole</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Chronic Motor Tic disorder</keyword>
	<keyword>Chronic Phonic Tic disorder</keyword>
	<keyword>Tourette's disorder</keyword>
	<keyword>Aripiprazole</keyword>
	<keyword>Abilify</keyword>
	<keyword>Children</keyword>
	<keyword>Adolescent</keyword>
</DOC>